The emerging role of psilocybin and MDMA in the treatment of mental illness

References

• Eaton JW, Weil RJ Culture and mental disorders. Glencoe, Ill: Free Press. Glencoe; 1955.
   Google Scholar
• NIMH » Mental Illness. n.d. [cited 2020 May 6]. Available from: https://www.nimh.nih.gov/health/statistics/mental-illness.shtml
   Google Scholar
• Doran CM, Kinchin I A review of the economic impact of mental illness. Aust Health Rev 2019;43(1):43–48. DOI: 10.1071/AH16115
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. FOCUS 2008;6:128–142. DOI: 10.1176/foc.6.1.foc128. 1
   Google Scholar
• Roy-Byrne P Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci 2015;17:191–206.
   PubMed Web of Science ®Google Scholar
• Dean OM, Gliddon E, Van Rheenen TE, et al. An update on adjunctive treatment options for bipolar disorder. Bipolar Disord 2018;20:87–96.
   PubMed Web of Science ®Google Scholar
• Rodriguez P, Holowka DW, Marx BP Assessment of posttraumatic stress disorder-related functional impairment: a review. J Rehabil Res Dev 2012;49:649–665.
   PubMed Web of Science ®Google Scholar
• Wasson RG, Hofmann A, Ruck CAP The road to Eleusis: unveiling the secret of the mysteries. Harcourt Brace Jovanovich; 1978.
   Google Scholar
• Hofmann A, Heim R, Brack A, et al. Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim. Experientia 1958;14:107–109.
   PubMedGoogle Scholar
• Carhart-Harris RL, Goodwin GM The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 2017;42:2105–2113.
   PubMed Web of Science ®Google Scholar
• Mahapatra A, Gupta R Role of psilocybin in the treatment of depression. Ther Adv Psychopharmacol 2017;7:54–56.
   PubMed Web of Science ®Google Scholar
• Kraehenmann R, Schmidt A, Friston K, et al. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin 2016;11:53–60.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998;9:3897–3902.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3:619–627. DOI: 10.1016/s2215-0366(16)30065-7.
   PubMed Web of Science ®Google Scholar
• Battaglia G, Brooks BP, Kulsakdinun C, et al. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988;149:159–163.
   PubMed Web of Science ®Google Scholar
• Shulgin AT, Nichols DE Characterization of three new psychotomimetics. Psychopharmacol Hallucinogens 1978:74–83.
   Google Scholar
• Greer G, Tolbert R Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986;18:319–327.
   PubMed Web of Science ®Google Scholar
• Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621–2624.
   PubMed Web of Science ®Google Scholar
• Heils A, Mössner R, Lesch KP The human serotonin transporter gene polymorphism–basic research and clinical implications. J Neural Transm 1997;104:1005–1014.
   PubMed Web of Science ®Google Scholar
• Cole JC, Sumnall HR The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003;27:199–217.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev 2017;49:84–91.
   PubMed Web of Science ®Google Scholar
• Tylš F, Páleníček T, Horáček J. Psilocybin – Summary of knowledge and new perspectives. Eur Neuropsychopharmacol 2014;24:342–356. DOI: 10.1016/j.euroneuro.2013.12.006.
   PubMed Web of Science ®Google Scholar
• Nichols DE Hallucinogens. Pharmacol Ther 2004;101:131–181.
   PubMed Web of Science ®Google Scholar
• Wing LL, Tapson GS, Geyer MA. 5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology (Berl) 1990;100:417–425.
   PubMed Web of Science ®Google Scholar
• Van Oekelen D, Luyten WHML, Leysen JE 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003;72:2429–2449.
   PubMed Web of Science ®Google Scholar
• Gresch PJ, Smith RL, Barrett RJ, et al. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacology 2005;30:1693–1702.
   PubMed Web of Science ®Google Scholar
• Weisstaub NV, Zhou M, Lira A, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006;313:536–540.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Kometer M The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010;11:642–651.
   PubMed Web of Science ®Google Scholar
• J-C B, Imad M, Mladenovic L, et al. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 2007;104:9870–9875.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 2018;70:621–660.
   PubMed Web of Science ®Google Scholar
• Coyle CM, Laws KR The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharm Clin 2015;30:152–163.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl) 2019;236:2735–2745.
   PubMed Web of Science ®Google Scholar
• Dos Santos RG, Dos Santos RG, Osório FL, et al. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol 2016;6:193–213. DOI: 10.1177/2045125316638008.
   PubMed Web of Science ®Google Scholar
• Daniel J, Haberman M Clinical potential of psilocybin as a treatment for mental health conditions. Ment Health Clin 2017;7:24–28.
   PubMedGoogle Scholar
• Rubio-Araiz A, Perez-Hernandez M, Urrutia A, et al. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) disrupts blood-brain barrier integrity through a mechanism involving P2X7 receptors. Int J Neuropsychopharmacol 2014;17:1243–1255.
   PubMed Web of Science ®Google Scholar
• Green AR, Richard Green A, Mechan AO, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pharmacol Rev 2003;55:463–508. DOI: 10.1124/pr.55.3.3.
   PubMed Web of Science ®Google Scholar
• Steele TD, Nichols DE, Yim GKW Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987;36:2297–2303. DOI: 10.1016/0006-2952(87)90594-6.
   PubMed Web of Science ®Google Scholar
• Patel R, Titheradge D MDMA for the treatment of mood disorder: all talk no substance? Ther Adv Psychopharmacol 2015;5:179–188.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Vollenweider FX The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in healthy volunteers. J Psychopharmacol 2000;14:269–274.
   PubMed Web of Science ®Google Scholar
• Greenway KT, Garel N, Jerome L, et al. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Rev Clin Pharmacol 2020;6:655–670
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68:71–78.
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016;30:1165–1180.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 2016;30:1181–1197.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Griffiths RR, Hendricks PS, et al. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology 2018;142:143–166.
   PubMed Web of Science ®Google Scholar
• Isbell H, Wolbach AB, Wikler A, et al. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147–159.
   PubMed Web of Science ®Google Scholar
• Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol 2002;7:357–364.
   PubMed Web of Science ®Google Scholar
• Wolbach AB Jr, Miner EJ, Isbell H Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 1962;3:219–223.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2011;25:439–452. DOI: 10.1177/0269881110378371.
   PubMed Web of Science ®Google Scholar
• Sessa B, Higbed L, Nutt D A Review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry 2019;10:138.
   PubMed Web of Science ®Google Scholar
• McCann UD, Ridenour A, Shaham Y, et al. Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; “Ecstasy”): a controlled study in humans. Neuropsychopharmacology 1994;10:129–138. DOI: 10.1038/npp.1994.15.
   PubMed Web of Science ®Google Scholar
• Steele TD, McCANN UD, Ricaurte GA 3, 4-Methylenedioxymethamphetamine (MDMA,“Ecstasy”): pharmacology and toxicology in animals and humans. Addiction 1994;89:539–551.
   PubMed Web of Science ®Google Scholar
• Commins DL, Vosmer G, Virus RM, et al.. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338–345.
   PubMed Web of Science ®Google Scholar
• Callahan BT, Cord BJ, Ricaurte GA Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 2001;40:113–121. DOI: 10.1002/syn.1032.
   PubMed Web of Science ®Google Scholar
• Kalant H The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ 2001;165:917–928.
   PubMed Web of Science ®Google Scholar
• Parrott AC Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 2004;173:234–241.
   PubMed Web of Science ®Google Scholar
• Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71:837–844.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Gamma A, Vollenweider FX Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 2001;154:161–168.
   PubMed Web of Science ®Google Scholar
• Freedman RR, Johanson C-E, Tancer ME Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2005;183:248–256.
   PubMed Web of Science ®Google Scholar
• Schifano F, Corkery J, Naidoo V, et al. Overview of amphetamine-type stimulant mortality data–UK, 1997–2007. Neuropsychobiology 2010;61:122–130.
   PubMed Web of Science ®Google Scholar
• Cami J, Farré M, Mas M, et al. Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol 2000;20:455–466.
   PubMed Web of Science ®Google Scholar
• Bedi G, Hyman D, de Wit H Is ecstasy an “empathogen”? Effects of±3, 4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 2010;68:1134–1140.
   PubMed Web of Science ®Google Scholar
• Parrott AC Residual neurocognitive features of ecstasy use: a re-interpretation of Halpern et al. (2011) consistent with serotonergic neurotoxicity. Addiction 2011;106:1365–1368.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick MG, Gunderson EW, Perez AY, et al. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2012;219:109–122.
   PubMed Web of Science ®Google Scholar
• Parrott AC The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology (Berl) 2007;191:181–193.
   PubMed Web of Science ®Google Scholar
• Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev 2018;84:272–288.
   PubMed Web of Science ®Google Scholar
• Dale E, Bang-Andersen B, Sánchez C Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 2015;95:81–97.
   PubMed Web of Science ®Google Scholar
• Godlewska BR, Browning M, Norbury R, et al.. Predicting treatment response in depression: the role of anterior cingulate cortex. Int J Neuropsychopharmacol 2018;21:988–996.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Suppes T, Tandon R, et al. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry 2017;78:703–713.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Nestler EJ The molecular neurobiology of depression. Nature 2008;455:894–902.
   PubMed Web of Science ®Google Scholar
• Majumder I, White JM, Irvine RJ Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression. Behav Pharmacol 2011;22:758–765.
   PubMed Web of Science ®Google Scholar
• de Win MML, de Win MML, Reneman L, et al. Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 2004;173:376–382. DOI: 10.1007/s00213-003-1723-4.
   PubMed Web of Science ®Google Scholar
• Matthews AJ, Bruno R An investigation of factors associated with depressive symptoms among a sample of regular ecstasy consumers. Neuropsychobiology 2010;61:215–222.
   PubMed Web of Science ®Google Scholar
• Majumder I, White JM, Irvine RJ Antidepressant‐like effects of ecstasy in subjects with a predisposition to depression. Addict Behav 2012;37:1189–1192.
   PubMed Web of Science ®Google Scholar
• Zhang MW, Ho R Critical Appraisal of Existing Ketamine Trials: existing limitations and limited applicability for treatment. Am J Psychiatry 2016;173:431.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Roseman L, Bolstridge M, et al.Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 2017;7:13187
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Grob CS, Brewerton TD Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 2016;3:481–488.
   PubMed Web of Science ®Google Scholar
• Roseman L, Nutt DJ, Carhart-Harris RL Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 2017;8:974.
   PubMed Web of Science ®Google Scholar
• Charlson F, van Ommeren M, Flaxman A, et al. WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. Lancet 2019;394:240–248.
   PubMed Web of Science ®Google Scholar
• Aderka IM, Hofmann SG, Nickerson A, et al. Functional impairment in social anxiety disorder. J Anxiety Disord 2012;26:393–400.
   PubMed Web of Science ®Google Scholar
• Weiss SJ, Simeonova DI, Kimmel MC, et al. Anxiety and physical health problems increase the odds of women having more severe symptoms of depression. Arch Womens Ment Health 2016;19:491–499.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington, VA: American Psychiatric Pub; 2013.
   Google Scholar
• National comorbidity survey. n.d. [cited 2020 May 7]. Available from: https://www.hcp.med.harvard.edu/ncs/index.php
   Google Scholar
• Brady KT, Back SE, Coffey SF Substance abuse and posttraumatic stress disorder. Curr Dir Psychol Sci 2004;13:206–209.
   Web of Science ®Google Scholar
• Sessa B Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 2007;21:220–224.
   PubMed Web of Science ®Google Scholar
• Oehen P, Traber R, Widmer V, et al. A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol 2013;27:40–52. DOI: 10.1177/0269881112464827.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Gamma A, Liechti M, et al. Psychological and cardiovascular effects and short-term sequelae of MDMA (“Ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998;19:241–251.
   PubMed Web of Science ®Google Scholar
• Sessa B MDMA and PTSD treatment: “PTSD: from novel pathophysiology to innovative therapeutics.” Neurosci Lett 2017;649:176–180.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, et al.Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 2013;27:28–39. DOI: 10.1177/0269881112456611.
   PubMed Web of Science ®Google Scholar
• G M O, Grigsby J, Poulter B, et al. 3,4-Methylenedioxymethamphetamine-assistedpsychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol 2018;32:1295–1307.
   PubMed Web of Science ®Google Scholar
• Bouso JC, Doblin R, Farré M, et al. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs 2008;40:225–236.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Mithoefer AT, Feduccia AA, et al.3,4-methyle nedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 2018;5:486–497. DOI: 10.1016/s2215-0366(18)30135-4. .
   PubMed Web of Science ®Google Scholar
• Gorman I, Belser AB, Jerome L, et al. Posttraumatic growth after MDMA‐assisted psychotherapy for posttraumatic stress disorder. J Trauma Stress 2020;33:161–170.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Liechti ME, Gamma A, et al. Acute psychological and neurophysiological effects of MDMA in humans. J Psychoactive Drugs 2002;34:171–184.
   PubMed Web of Science ®Google Scholar
• Harris DS, Baggott M, Mendelson JH, et al. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002;162:396–405.
   PubMed Web of Science ®Google Scholar
• Croft RJ, Mackay AJ, Mills AT, et al. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology (Berl) 2001;153:373–379.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Price LH, Opsahl C, et al. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am J Drug Alcohol Abuse 1992;18:331–341. DOI: 10.3109/00952999209026070.
   PubMed Web of Science ®Google Scholar
• Piper BJ A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 2007;29:288–300. DOI: 10.1016/j.ntt.2006.10.002.
   PubMed Web of Science ®Google Scholar
• Wilcox JA Psilocybin and obsessive compulsive disorder. J Psychoactive Drugs 2014;46:393–395.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006;67:1735–1740.
   PubMed Web of Science ®Google Scholar
• Kuypers KPC, de la Torre R, Farre M, et al. Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. Sci Rep 2018;8:1061.
   PubMed Web of Science ®Google Scholar
• Pratt LA, Brody DJ, Gu Q Antidepressant use among persons aged 12 and over: United States, 2011-2014. NCHS data brief. number 283. National Center for Health Statistics. United States. 2017.
   Google Scholar
• Bambauer KZ, Adams AS, Zhang F, et al. Physician alerts to increase antidepressant adherence: fax or fiction? Arch Intern Med 2006;166:498–504.
   PubMedGoogle Scholar
• Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821–1825.
   PubMed Web of Science ®Google Scholar
• Nutt D, Erritzoe D, Carhart-Harris R Psychedelic psychiatry’s brave new world. Cell 2020;181:24–28.
   PubMed Web of Science ®Google Scholar